BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 31,600 shares, a growth of 24.4% from the February 28th total of 25,400 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 87,400 shares, the short-interest ratio is presently 0.4 days.
BiomX Price Performance
Shares of BiomX stock traded down $0.06 during trading hours on Tuesday, reaching $0.49. 154,152 shares of the company’s stock were exchanged, compared to its average volume of 92,832. The company has a market cap of $8.96 million, a price-to-earnings ratio of -0.15 and a beta of 1.27. BiomX has a fifty-two week low of $0.48 and a fifty-two week high of $4.99.
Wall Street Analyst Weigh In
Separately, HC Wainwright lifted their price objective on shares of BiomX from $2.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday.
BiomX Company Profile
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Featured Articles
- Five stocks we like better than BiomX
- Basic Materials Stocks Investing
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- How to Read Stock Charts for Beginners
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Golden Cross Stocks: Pattern, Examples and Charts
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
